Rivero-Santana Amado, Cuéllar-Pompa Leticia, Sánchez-Gómez Luis M, Perestelo-Pérez Lilisbeth, Serrano-Aguilar Pedro
Canarian Foundation of Health and Research (FUNCIS), Camino Candelaria, n° 44, 1ª planta, El Rosario, 38109 Tenerife, Spain; Health Services Research on Chronic Patients Network (REDISSEC), Camino Candelaria, 44, El Rosario, 38109 Tenerife, Spain; Center for Biomedical Research of the Canary Islands (CIBICAN), Campus de Ciencias de la Salud, s/n, 38071 La Laguna, Spain.
Canarian Foundation of Health and Research (FUNCIS), Camino Candelaria, n° 44, 1ª planta, El Rosario, 38109 Tenerife, Spain; Health Services Research on Chronic Patients Network (REDISSEC), Camino Candelaria, 44, El Rosario, 38109 Tenerife, Spain; Center for Biomedical Research of the Canary Islands (CIBICAN), Campus de Ciencias de la Salud, s/n, 38071 La Laguna, Spain.
Health Policy. 2014 Mar;115(1):82-91. doi: 10.1016/j.healthpol.2013.12.007. Epub 2013 Dec 28.
In the last years there has been a significant increase in reported cases of pertussis in developed countries, in spite of high rates of childhood immunization. Health institutions have recommended different vaccination strategies to reduce child morbidity and mortality: vaccination of adolescents and adults, pregnant women, people in contact with the newborn (cocoon strategy) and health care workers. The aim of this paper is to review the scientific evidence supporting these recommendations.
Systematic review on the effectiveness and cost-effectiveness of the above strategies for the reduction of morbidity and mortality from pertussis in infants under 12 months. The electronic databases Medline, PreMedline, Embase, CRD, Cochrane Central, and Trip Database were consulted from 1990 to October 2012. The evidence was assessed using the GRADE system.
There were eight studies on the efficacy or safety of the strategies analyzed, and 18 economic evaluations. Direct evidence on the efficacy of these strategies is scarce. Economic evaluations suggest that vaccination of adolescents and adults would be cost-effective, although there is major uncertainty over the parameters used.
From the perspective of health technology assessment, there is insufficient evidence to recommend the vaccination strategies evaluated.
尽管儿童免疫接种率很高,但在过去几年中,发达国家报告的百日咳病例数仍显著增加。卫生机构推荐了不同的疫苗接种策略以降低儿童发病率和死亡率:青少年和成人、孕妇、与新生儿接触者(茧式策略)以及医护人员的疫苗接种。本文旨在综述支持这些建议的科学证据。
对上述策略降低12个月以下婴儿百日咳发病率和死亡率的有效性及成本效益进行系统评价。检索了1990年至2012年10月的电子数据库Medline、PreMedline、Embase、CRD、Cochrane Central和Trip数据库。使用GRADE系统对证据进行评估。
有八项关于所分析策略有效性或安全性的研究,以及18项经济评价。关于这些策略有效性的直接证据很少。经济评价表明,青少年和成人接种疫苗具有成本效益,尽管所使用的参数存在很大不确定性。
从卫生技术评估的角度来看,没有足够的证据推荐所评估的疫苗接种策略。